Join
Live feed
·
PRReleasevia Quantisnow
ArriVent BioPharma Inc. logo

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

ByQuantisnow·Wall Street's wire, on your screen.
AVBP· ArriVent BioPharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AVBP (ArriVent BioPharma Inc.) and more on Quantisnow.